A study using the REIN registry suggests a statin therapy benefits for secondary prevention in patients receiving dialysis

医学 二级预防 重症监护医学 透析 急诊医学 内科学 肾脏疾病 梅德林 他汀类 透析疗法 初级预防 肾病科
作者
Pierre Letourneau,Laetitia Koppe,C. Couchoud,Solène M. Laville,Antoine Gavoille,Mikaïl Nourredine
出处
期刊:Kidney International [Elsevier BV]
标识
DOI:10.1016/j.kint.2026.09.027
摘要

INTRODUCTION: While statins are effective for cardiovascular prevention in the general population, their benefit in patients with CKD G5D (kidney failure treated by dialysis) remains uncertain. Previous randomized controlled trials included mixed populations for primary and secondary prevention while excluding patients with recent cardiovascular events, leaving a knowledge gap regarding statin effectiveness for secondary prevention immediately following an atherosclerotic cardiovascular disease (ASCVD) event. Here, we address this gap by providing real-world evidence. METHODS: We conducted a landmark-based observational study, informed by the target trial framework using the French Renal Epidemiology and Information Network (REIN) registry and merged with data from the French national healthcare system database from 2010 to 2023. We included adults with CKD G5D who experienced an ASCVD event. We used inverse probability of treatment weighting to balance baseline characteristics between statin initiators and non-initiators, thereby estimating the average causal effect on all-cause mortality. Results focus on the relative and absolute risk difference and the life expectancy gain using delta restricted mean survival time (dRMST). RESULTS: The study cohort included 5534 patients (median age: 75 years; 67% male). During the ten years of follow-up, statin use was associated with a reduced risk of mortality. The survival curves reached a maximum absolute difference at year four (risk difference -6.2% (95% CI: -10.2; -2.2); relative risk 0.88 [95% CI: 0.81; 0.96]). Life expectancy extended significantly over time with a mean survival gain of 69 days at five years (95% CI: 14-125) and reaching 135 days at ten years (95% CI: 31-239). No difference was identified between groups regarding hospitalizations for rhabdomyolysis or toxic hepatitis. CONCLUSIONS: In patients receiving dialysis, statin initiation following an ASCVD event is safe and associated with a modest-to-moderate ten-year cumulative survival benefit. While interpreted within observational limitations, this real-world evidence supports their use in this secondary prevention setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大胆的灵雁完成签到,获得积分10
刚刚
刚刚
HHHH完成签到,获得积分10
刚刚
蛀虫完成签到 ,获得积分10
1秒前
1秒前
迅速金毛完成签到,获得积分10
1秒前
图书馆完成签到,获得积分10
1秒前
2秒前
Ttttt发布了新的文献求助10
2秒前
邓统浩完成签到,获得积分10
2秒前
吃饭饭发布了新的文献求助10
2秒前
爱唱狐狸的番茄小子完成签到,获得积分10
2秒前
3秒前
zz321完成签到,获得积分0
3秒前
洁净如音完成签到,获得积分10
3秒前
MMQ完成签到,获得积分10
3秒前
111发布了新的文献求助10
3秒前
小张在进步完成签到,获得积分10
3秒前
3秒前
3秒前
尊敬的寄松的应助被Samuel采纳,获得30
3秒前
4秒前
规格严格功夫到家完成签到,获得积分10
4秒前
威武的友琴完成签到,获得积分10
4秒前
Hello的应助被吃完睡h采纳,获得10
4秒前
4秒前
lemon完成签到,获得积分10
4秒前
所所的应助被北岭梅花香到骨采纳,获得10
4秒前
跳跃小笼包完成签到,获得积分10
5秒前
隐形曼青的应助被hbutsj采纳,获得10
5秒前
深情安青的应助被Qiancheng采纳,获得10
5秒前
福履齐长完成签到 ,获得积分10
5秒前
licomen完成签到,获得积分10
5秒前
hiimsakura完成签到,获得积分10
5秒前
sunidea发布了新的文献求助10
6秒前
Vi完成签到,获得积分10
6秒前
6秒前
dbc1234完成签到,获得积分10
6秒前
羊羊羊完成签到,获得积分10
7秒前
wangmengcheng完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159790
求助须知:如何正确求助?哪些是违规求助? 9555224
关于积分的说明 21726021
捐赠科研通 7749765
什么是DOI,文献DOI怎么找? 3427296
关于科研通互助平台的介绍 2552375
邀请新用户注册赠送积分活动 2471654